leisure time -WSS

leisure time

author：entertainment 2025-09-05 06:06:51 - browse：84

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

focus

WSS

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Senate panel puts off hardest PBM reforms for another day

What American doctors can learn from their Israeli counterparts

What causes rare myocarditis in young men after Covid vaccines?

Why patients can’t get everything they want on drug pricing

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Senate panel puts off hardest PBM reforms for another day

BioMarin wins approval for gene therapy to treat hemophilia A

Roche’s Alnylam deal shows drug firms interested in heart drugs

The cancer drug shortage isn’t new — and neither are the solutions

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Cancer drug shortages should be causing more outrage

A new crop of companies is reshaping the health data economy

Cancer drug shortages should be causing more outrage

What to watch for from Zogenix and Amicus clinical trials

hotspot

The (many) problems with a new study criticizing cancer screening

Amazon on where the company's health care bets are headed next

Ethical issues complicate the benefits of medical crowdfunding

A new crop of companies is reshaping the health data economy

What causes rare myocarditis in young men after Covid vaccines?

Truvian presents data for its desktop blood

focus

focus

leisure time

focus